Name | TD-5471 hydrochloride |
---|---|
Synonyms |
2(1H)-Quinolinone, 8-hydroxy-5-[(1R)-1-hydroxy-2-[[2-[4-[(6-methoxy[1,1'-biphenyl]-3-yl)amino]phenyl]ethyl]amino]ethyl]-, hydrochloride (1:1)
8-Hydroxy-5-{(1R)-1-hydroxy-2-[(2-{4-[(6-methoxy-3-biphenylyl)amino]phenyl}ethyl)amino]ethyl}-2(1H)-quinolinone hydrochloride (1:1) |
Description | TD-5471 hydrochloride is a potent and selective full agonist of the human β2-adrenoceptor. |
---|---|
Related Catalog | |
Target |
β2 adrenoceptor[1] |
In Vitro | TD-5471 is potent, with slow onset in an in vitro guinea pig trachea model. TD-5471 has potency with pEC50 of 8.7 in the guinea pig tracheal ring assay.TD-5471 is structurally differentiated from Milveterol and its long duration of action is consistent with a correlation with hydrophobicity observed in other long-acting β2-agonist discovery programs[1]. |
In Vivo | TD-5471 shows a dose-dependent and long duration of action in an in vivo guinea pig model of bronchoprotection. In a guinea pig model of in vivo bronchoprotection, TD-5471 shows excellent potency (measured 1.5 h after nebulized dosing). Because a high dose of Salmeterol (300 μg/mL) provides bronchoprotection lasting ≥24 h in this model, a 72 h time point is selected to provide confidence that TD-5471 will be suitable for once-daily dosing in man. TD-5471-mediated bronchoprotection at 72 h is dose-dependent and is significantly greater than that of Salmeterol at nebulizer concentrations of ≥30 μg/mL[1]. |
References |
Molecular Formula | C32H32ClN3O4 |
---|---|
Molecular Weight | 558.067 |
Exact Mass | 557.208130 |